WO2001009094A3 - Chemokine receptor antagonists and methods of use therefor - Google Patents
Chemokine receptor antagonists and methods of use therefor Download PDFInfo
- Publication number
- WO2001009094A3 WO2001009094A3 PCT/US2000/020607 US0020607W WO0109094A3 WO 2001009094 A3 WO2001009094 A3 WO 2001009094A3 US 0020607 W US0020607 W US 0020607W WO 0109094 A3 WO0109094 A3 WO 0109094A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- receptor antagonists
- chemokine receptor
- use therefor
- nr50r5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00952261A EP1204640A2 (en) | 1999-07-28 | 2000-07-28 | Chemokine receptor antagonists and methods of use therefor |
AU64991/00A AU6499100A (en) | 1999-07-28 | 2000-07-28 | Chemokine receptor antagonists and methods of use therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36280799A | 1999-07-28 | 1999-07-28 | |
US09/362,807 | 1999-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001009094A2 WO2001009094A2 (en) | 2001-02-08 |
WO2001009094A3 true WO2001009094A3 (en) | 2001-07-05 |
Family
ID=23427612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/020607 WO2001009094A2 (en) | 1999-07-28 | 2000-07-28 | Chemokine receptor antagonists and methods of use therefor |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1204640A2 (en) |
AU (1) | AU6499100A (en) |
WO (1) | WO2001009094A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
TWI291467B (en) | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002151A2 (en) * | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1999037619A1 (en) * | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1999037617A1 (en) * | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2000014089A1 (en) * | 1998-09-04 | 2000-03-16 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
-
2000
- 2000-07-28 EP EP00952261A patent/EP1204640A2/en not_active Withdrawn
- 2000-07-28 WO PCT/US2000/020607 patent/WO2001009094A2/en not_active Application Discontinuation
- 2000-07-28 AU AU64991/00A patent/AU6499100A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002151A2 (en) * | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1999037619A1 (en) * | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1999037617A1 (en) * | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2000014089A1 (en) * | 1998-09-04 | 2000-03-16 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
Also Published As
Publication number | Publication date |
---|---|
EP1204640A2 (en) | 2002-05-15 |
WO2001009094A2 (en) | 2001-02-08 |
AU6499100A (en) | 2001-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001009138A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
ID26618A (en) | CHEMOKINE RECEPTOR ANTAGONISTS AND THE METHOD OF USE | |
WO1998002151A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
WO2002085861A8 (en) | Imidazolidine compounds and their use as cxcr3 antagonists | |
WO1999007351A3 (en) | Indole derivatives and their use as mcp-1 antagonists | |
MX9804597A (en) | Naphthyl-substituted benzimidazole derivatives as anticoagulants. | |
EA200100058A1 (en) | 4-BENZYLPIPERIDINALKYLSULPHOXIDE HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS A SUBTYPE-ELECTORAL ANTAGONISTS OF NMDA-RECEPTORS | |
EA200101156A1 (en) | DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC | |
KR910007927A (en) | Condensed imidazole derivatives and preparation methods thereof | |
ATE524176T1 (en) | VALSARTAN TABLET | |
HK1038926B (en) | Crf receptor antagonists and methods relating thereto | |
AP2002002664A0 (en) | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. | |
HK1038925A1 (en) | Crf receptor antagonists and methods relating thereto crf | |
CA2326339A1 (en) | Use of dexmedetomidine for icu sedation | |
WO2003045942A3 (en) | Chemokine receptor antagonists and methods of use thereof | |
WO1997010824A8 (en) | Use of 5ht1b receptor antagonist for the treatment of vascular disease | |
WO2001009119A3 (en) | Chemokine receptor antagonists | |
SG165152A1 (en) | Chemokine receptor antagonists and methods of use thereof | |
WO2001009094A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
HU9801792D0 (en) | 4-aminopyrrole(3,2-d)pyrimidines as neuropeptide y receptor antagonists | |
CA2322229A1 (en) | Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity | |
WO2000076457A3 (en) | Il-8 receptor antagonists | |
PT2266558T (en) | Treatment of neuropathic pain with the n-methyl-d-aspartate (nmda) receptor antagonist dextromethorphan | |
EA200401617A1 (en) | COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER'S Disease | |
MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000952261 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000952261 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000952261 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |